Cargando…

An immune-based tool platform for in vivo cell clearance

Immunological targeting of pathological cells has been successful in oncology and is expanding to other pathobiological contexts. Here, we present a flexible platform that allows labeling cells of interest with the surface-expressed model antigen ovalbumin (OVA), which can be eliminated via either a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jieqiong, Tsukui, Tatsuya, Wu, Xiumin, Brito, Alyssa, Trumble, John Maxwell, Caraballo, Juan C, Allen, Greg M, Zavala-Solorio, José, Zhang, Chunlian, Paw, Jonathan, Lim, Wendell A, Geng, Jiefei, Kutskova, Yuliya, Freund, Adam, Kolumam, Ganesh, Sheppard, Dean, Cohen, Robert L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264967/
https://www.ncbi.nlm.nih.gov/pubmed/37311583
http://dx.doi.org/10.26508/lsa.202201869
Descripción
Sumario:Immunological targeting of pathological cells has been successful in oncology and is expanding to other pathobiological contexts. Here, we present a flexible platform that allows labeling cells of interest with the surface-expressed model antigen ovalbumin (OVA), which can be eliminated via either antigen-specific T cells or newly developed OVA antibodies. We demonstrate that hepatocytes can be effectively targeted by either modality. In contrast, pro-fibrotic fibroblasts associated with pulmonary fibrosis are only eliminated by T cells in initial experiments, which reduced collagen deposition in a fibrosis model. This new experimental platform will facilitate development of immune-based approaches to clear potential pathological cell types in vivo.